MARKET
IPO

GRAL

Grail, Inc.
GRAL
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
Biotechnology & Medical Research
2020-09-09
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: Pending
Listed
'More Than 400 Grail Patients Incorrectly Told They May Have Cancer' - Financial Times
Benzinga · 06/02/2023 19:21
About GRAL
GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

Webull offers Grail, Inc. stock information, including NASDAQ: GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.